home / stock / ngen:cc / ngen:cc quote
Last: | $2.24 |
---|---|
Change Percent: | -6.67% |
Open: | $2.34 |
Close: | $2.24 |
High: | $2.4 |
Low: | $2.24 |
Volume: | 40,579 |
Last Trade Date Time: | 05/06/2022 04:56:09 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.24 | $2.34 | $2.24 | $2.4 | $2.24 | 40,579 | 05-06-2022 |
$2.4 | $2.32 | $2.4 | $2.4 | $2.32 | 31,105 | 05-05-2022 |
$2.32 | $2.39 | $2.32 | $2.46 | $2.32 | 69,229 | 05-04-2022 |
$2.36 | $2.42 | $2.36 | $2.67 | $2.36 | 148,152 | 05-03-2022 |
$2.46 | $2.27 | $2.46 | $2.5 | $2.27 | 136,875 | 05-02-2022 |
$2.24 | $2.23 | $2.24 | $2.27 | $2.16 | 21,106 | 04-29-2022 |
$2.24 | $2.21 | $2.24 | $2.39 | $2.2 | 29,502 | 04-28-2022 |
$2.21 | $2.22 | $2.21 | $2.22 | $1.975 | 81,861 | 04-27-2022 |
$2.22 | $2.3 | $2.22 | $2.31 | $2.22 | 21,400 | 04-26-2022 |
$2.3 | $2.4 | $2.3 | $2.49 | $2.3 | 89,546 | 04-25-2022 |
$2.41 | $2.35 | $2.41 | $2.51 | $2.35 | 163,031 | 04-22-2022 |
$2.34 | $2.29 | $2.34 | $2.38 | $2.22 | 57,915 | 04-21-2022 |
$2.3 | $2.23 | $2.3 | $2.3 | $2.22 | 54,214 | 04-20-2022 |
$2.23 | $2.25 | $2.23 | $2.29 | $2.18 | 84,958 | 04-19-2022 |
$2.25 | $2.2 | $2.25 | $2.26 | $2.16 | 49,724 | 04-18-2022 |
$2.22 | $2.26 | $2.22 | $2.26 | $2.14 | 56,548 | 04-15-2022 |
$2.22 | $2.26 | $2.22 | $2.26 | $2.14 | 56,348 | 04-14-2022 |
$2.26 | $2.21 | $2.26 | $2.27 | $2.17 | 26,686 | 04-13-2022 |
$2.2 | $2.2 | $2.2 | $2.22 | $2.12 | 30,070 | 04-12-2022 |
$2.2 | $2.12 | $2.2 | $2.2 | $2.08 | 45,425 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
Nervgen Pharma Corp. Company Name:
NGEN:CC Stock Symbol:
TSXVC Market:
Nervgen Pharma Corp. Website:
New molecule demonstrates efficacy in a challenging SCI model Expanding pipeline into new indications of ischemic stroke and ALS Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to ...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) , a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, w...
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical ...